Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Robin R Frey

Todd M Hansen

Michael L Curtin

George A Doherty

Michael Michaelides

Andrew J Souers

Xiaohong Song

Le Wang

Zhi-Fu Tao

Milan Bruncko

Howard Robin Heyman

Xilu Wang

Michael D Wendt

Aaron R Kunzer

Gerard M Sullivan

Andrew S Judd

Steven K Davidsen

Richard F Clark

Zhiqin Ji

Carol K Wada

Bryan K Sorensen

Gavin C Hirst

Kenton L Longenecker

David J Calderwood

Paul Rafferty

Kelly Mullen

Andrew Burchat

Michael R Michaelides

Peter Hrnciar

Heather M Davis

Patrick Betschmann

Melanie A Muckey

Thomas Dale Penning

Yunsong Tong

Marina Pliushchev

Ramzi Farah Sweis

Chunqiu Lai

Augustine Osuma

Andy Judd

John K Pratt

Lee Daniel Arnold

Dachun Liu

William J McClellan

Kevin R Woller

Keith F McDaniel

Keith W Woods

Gui-Dong Zhu

Alan S Florjancic

Yan Guo

James H Holms

Jianchun Gong

Yujia Dai

Neil Wishart

Douglas H Steinman

Anthony Mastracchio

Guidong Zhu

Jane Gong

Rajeev Goswami

Roberto M Risi

Omprakash Reddy Iguturi

Madhu Babu Dabbeeru

Juliem Miyashiro

Andrew F Burchat

Milan Brunko

William J Mcclellan

Howard R Heyman

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

The present invention provides for compounds of formula (I) wherein R, X, Y, Y, L, A, A, A, A, A, A, A, and A, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I). 

Bromodomain inhibitors

Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds of Formula (IIa), wherein R, R, R, R, R, R, R, and Rare as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors

Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, R, and Rare as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

Tetracyclic CDK9 kinase inhibitors

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

NAMPT inhibitors

Compounds that inhibit protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved safety profile due to low CYP3A4 inhibition, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

Thieno[3,2-C]pyridine kinase inhibitors with improved CYP safety profile

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, A, A, A, X and Y are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora and KDR.

Pyrimidine inhibitors of kinases

Growing community of inventors

Libertyville, IL, United States of America

Robin R Frey